Antiobesity drugs before and after bariatric surgery – how to make the best use of them

Czech version

Authors: Petra Šrámková; Martin Fried
Authors‘ workplace: OB klinika Praha
Published in: Čas. Lék. čes. 2022; 161: 107-113
Category: Review Article

Overview

Obesity as a chronic, serious, and progressive lifelong disease requires an active approach to treatment. Treatment means necessary adjustment of lifestyle with suitable regular physical activity, including pharmacological or bariatric support. Current pharmacological treatment can be an effective helper in the preparation for the surgical treatment of obesity (bariatric and metabolic operations), and in greater adherence of the patient to the necessary regime changes in life and in preoperative weight reduction. With the lapse of time after surgical treatment, in many cases we indicate the start of pharmacological treatment if the weight increases again. We do not yet know the appropriate types of patients and the exact indications for specific therapeutic modalities – a suitable antiobesity drug or type of bariatric surgery. The best long-term results come from a combination of at least two of these options, along with a lifestyle change. Among modern antiobesity drugs, there are naltrexone-bupropion and liraglutide. Orlistat can be mentioned from older ones.

Keywords:

obesity – liraglutide – bariatric surgery – set point – preoperative weight reduction – weight gain after bariatric surgery – naltrexone-bupropion

Sources

Harrison P. Obesity is a disease, not a choice, experts advise. Medscape, 2018. Dostupné na: www.medscape.com/viewarticle/896444
Svačina Š. Obezitologie a teorie metabolického syndromu. Triton, Praha, 2013: 33–40.
Apovian CM. The obesity epidemic – understanding the disease and the treatment. N Engl J Med 2016; 374: 177–179.
James W, Ralph A, Ferro-Luzzi A. Energy needs of the elderly. A new approach. In: Munro HN, Dunford DE (ed.). Nutrition, ageing and the elderly. Plenum Press, New York, London, 1989: 129–150.
Lin CK, Lin CC. Work of breathing and respiratory drive in obesity. Respirology 2012; 17: 402–411.
Cassie S, Menezes C, Birch DW et al. Effect of preoperative weight loss in bariatric surgical patients: a systematic review. Surg Obes Relat Dis 2011; 7: 760–767.
Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg 2011; 146: 1300–1305.
Thorell A, MacCormick AD, Awad S et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations. World J Surg 2016; 40: 2065–2083.
Gerber P, Anderin C, Gustafsson UO, Thorell A. Weight loss immediately prior to gastric bypass and postoperative weight change. Surg Obes Relat Dis 2016; 12: 556–562.
Chinaka U, Fultang J, Ali A et al. Pre-specified weight loss before bariatric surgery and postoperative outcomes. Cureus 2020; 12: e12406.
Iglesias P, Civantos S, Vega B et al. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery. Obes Surg 2015; 25: 575–578.
Ta D, Dang JT, Sharma AM et al. Use of Liraglutide in a tertiary bariatric clinic: a case series. J Obes Chronic Dis 2019; 3: 36–39.
Tek C. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence 2016; 10: 751–759.
Wang Z, Li X, Knoth R et al. Cost implication of using lorcaserin in weight management prior to bariatric surgery. Value Health 2015; 18: A295.
Abu Dayyeh BK, Maselli DB, Rapaka B et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet 2021; 398: 1965–1973.
Bariatric Surgery: Selection & Pre-Operative Work Up. Obesity Canada, 2022. Dostupné na: https://obesitycanada.ca/guidelines/preop
Sjöström L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56–65.
Adams TD, Davidson LE, Litwin SE et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 2017; 377: 1143–1155.
Nor Hanipah Z, Nasr EC, Bucak E et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis 2018; 14: 93–98.
Toth AT, Gomez G, Shukla AP et al. Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Children (Basel) 2018; 5: 116.
Rye P, Modi R, Cawsey S et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg 2018; 28: 3553–3558.
Wharton S, Kuk JL, Luszczynski M et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes 2019; 9: e12323.
A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery (COR-WR). ClinicalTrials.gov, 2020. Dostupné na: https://clinicaltrials.gov/ct2/show/record/NCT04587843?view=record
Waden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD Trial. Obesity (Silver Spring) 2011; 19: 110–120.
Hollander P, Gupta AK, Plodkowski R et al. Effects of naltrexone sustained – release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36: 4022–4029.
Nissen SE, Wolski KE, Prcela L et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016; 315: 990–1004.
Sposito AC, Bonilha I, Luchiari B et al. Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obes Rev 2021; 22: e13224.
Astrup A, Carraro R, Finer N et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (London) 2012; 36: 843–854.
Waden TA, Walsh OA, Berkowitz RI et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: A randomized controlled trial. Obesity (Silver Spring) 2019; 27: 75–86.
Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11–22.
Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.
Torgerson JS, Hauptman J, Boldrin MN et al. Xenical in the prevention of diabetes in obese subject (XENDOS) study: randomized study of orlistat as an adjunct to lifestyle changes for prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–161.

Labels

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Úvodem

Současnost a perspektivy léčby obezity: Co již víme a co můžeme očekávat?

Současná bariatrická/metabolická chirurgie

Nutriční péče o bariatrické pacienty

Recommendations for psychological assessment before bariatric surgery

Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection – a ten-year single-center experience

Bartter and Gitelman syndromes

Myocarditis as a manifestation of the disease COVID-19 and after vaccination against this disease

Anaesthesia for non-cardiac surgical procedures in patients after heart transplantation

Thoracoscopic approach in the treatment of thoracic duct injuries – case reports and review of the literature

Use of unmanned aerial systems in the health care

Current issues of body donation for teaching and research purposes and their use in the Czech Republic